THE TEMPO GROUP

PT. Tempo Scan Pacific Tbk

Head Office : Tempo Scan Tower, 16th floor, Jl. H.R. Rasuna Said Kav. 3-4, Jakarta 12950, Indonesia
Phone : 2921 8888 Fax : 2920 9999 PO BOX : 3269 Jkt 10002 No. P.B.F. : 31081/PBF/II/91
Factory : EJIP Industrial Park, Plot 1G-H, Lemahabang, Bekasi 17550 Phone : 897 1553, 8970801 Fax: 897 1563, 897 0764

PT TEMPO SCAN PACIFIC TBK
Robust First Half 2026 Financial Results

During the First Half of 2026, global economic and financial-market conditions remained highly uncertain. The escalation of conflict involving Iran and the broader Middle East disrupted energy and maritime transport markets, generating sharp increases in oil prices, freight rates, insurance costs and supply-chain uncertainty.

In Indonesia, the Rupiah came under substantial depreciation pressure, while Bank Indonesia increased its policy rate by a cumulative 100 basis points during May and June to preserve exchange-rate stability. However, capital flows remained volatile, including net outflows in the first quarter, while higher financing costs, cautious consumer spending and domestic political and policy developments continued to affect business confidence.

Notwithstanding these challenging conditions, **PT Tempo Scan Pacific Tbk ("Tempo Scan") achieved positive and broad-based growth in First Half 2026. Its consolidated net sales increased by 7.7% and amounted to Rp.7,109.9 billion**, compared with Rp.6,598.7 billion in First Half 2025. This growth was primarily driven by the Company's own and affiliate products, whose net sales rose by 9.6% to Rp.4,893.5 billion and accounted for 68.8% of the said consolidated net sales, compared with 67.6% in the corresponding period last year. This development was consistent with Tempo Scan's strategy of strengthening its own brand equities and proprietary product portfolio.

Tempo Scan's Pharmaceutical division ("**Pharma division**") and Consumer Products & Cosmetics division ("**CPC division**") recorded positive net sales growth of 8.6% and 10.6%, respectively, while its Distribution division's net sales only grew by 3.8%. Correspondingly, Tempo Scan's operating profit increased by 9.4% to Rp.885.6 billion. Its net profit after tax rose by 10.3% to Rp.774.8 billion, while its EBITDA increased by 9.8% to Rp.1,064.7 billion.

The principal contributors to Tempo Scan's First Half 2026 net sales performance were as follows:

1) **Tempo Scan's CPC division delivered the strongest net sales growth, with net sales increased by 10.6% to Rp.2,478.7 billion.** The division's Consumer Products group recorded net sales growth of 10.1% to Rp.1,957.2 billion, while its Cosmetics group achieved equally a commendable net sales growth of 12.7% to Rp.521.5 billion. The Consumer Products and Cosmetics groups contributed 79.0% and 21.0%, respectively, to the CPC division's net sales.

   From a geographical perspective, the CPC division's domestic net sales grew by 10.8% to Rp.2,359.4 billion, while its International Business net sales increased by 6.8% to Rp.119.3 billion. Consequently, the CPC division's contribution to Tempo Scan's consolidated net sales increased to 34.9%, compared with 34.0% in First Half 2025.

2) **Tempo Scan's Pharma division achieved net sales growth of 8.6% to Rp.2,414.8 billion.** The division's Consumer Health products, including Nutrition, increased by 8.8% to Rp.2,374.3 billion. Within this group, Consumer Health products excluding Nutrition rose by 10.7% to Rp.1,230.2 billion, while Nutrition products grew by 6.8% to Rp.1,144.1 billion. The Prescription Medicines group's net sales remained broadly stable at Rp.40.5 billion.

   The Pharma division's domestic net sales grew strongly by 10.9% to Rp.2,310.3 billion. The division's International Business net sales amounted to Rp.104.5 billion. Accordingly, the Pharma division contributed 34.0% to Tempo Scan's consolidated net sales, compared with 33.7% in First Half 2025.

3) **Tempo Scan's Distribution division recorded net sales growth of 3.8% to Rp.2,216.4 billion.** Net sales of external pharmaceutical principals' products rose by 19.7% to Rp.298.7 billion, while external non-pharmaceutical principals' products increased by 1.7% to Rp.1,917.7 billion. The Distribution division contributed 31.2% to Tempo Scan's consolidated net sales.

First Half 2026 Gross Profit and Gross Profit Margin

Tempo Scan's gross profit increased by 8.7% to Rp.2,654.2 billion, exceeding its net sales growth of 7.7%. Consequently, its consolidated gross profit margin has improved to 37.3%, from 37.0% in First Half 2025. This result was achieved despite higher costs for certain imported raw materials amongst other due to Rupiah weakening, oil-linked packaging materials price increase, higher fuel and freight cost following the escalation of conflict in the Middle East. The Company mitigated these pressures through service level continuous improvement, strategic procurement implementation, increasing manufacturing productivity, product-mix management and IT development including AI application.

Gross profit from Tempo Scan's Pharma division increased by 7.5% to Rp.1,173.3 billion, the CPC division increased by 11.1% to Rp.1,296.1 billion, while the Distribution division increased by 0.9% to Rp.184.8 billion.

First Half 2026 Operating Expenses and Profitability

Tempo Scan continued to exercise cost management discipline including over advertising and promotion activities and other operating expenditure, prioritising initiatives that supported its brand equities development, consumer conversion and sustainable sales growth. Its total selling expenses amounted to Rp.1,540.9 billion, an increase of 15.9%, reflecting continued commercial and brand-support activities. General and administrative expenses were effectively controlled, increasing by 4.7% to Rp.369.3 billion. Consequently, the ratio of such general and administrative expenses to net sales has declined to 5.2%, from 5.3% in First Half 2025.

In addition, its net other operating income increased to Rp.141.6 billion, compared with Rp.50.5 billion in the corresponding period last year. As a result, **Tempo Scan's operating profit grew by 9.4% to Rp.885.6 billion, while its operating profit margin improved to 12.5%, from 12.3% in First Half 2025**.

Tempo Scan's profit before tax increased by 7.3% to Rp.941.3 billion. More importantly, **its net profit after tax attributable to equity holders of the parent company grew by 10.3% to Rp.774.8 billion**, with the corresponding **net profit margin improving to 10.9%, compared to 10.6% in First Half 2025**. Earnings per share increased by 10.3% to Rp.172 in First Half 2026, from Rp.156 in the prior year period.

Tempo Scan's EBITDA increased by 9.8% to Rp.1,064.7 billion, while its EBITDA margin improved to 15.0%, from 14.7% in the corresponding period last year. These results reflected the Company's ability to translate healthy sales growth and a resilient gross profit margin into sustainable earnings growth.

Balance Sheet and Liquidity as of 30 June 2026

Tempo Scan maintained a very solid balance sheet as of 30 June 2026. Cash and cash equivalents increased by 22.4% to Rp.5,367.0 billion, compared with Rp.4,385.4 billion as of 30 June 2025. Total assets increased by 11.3% to Rp.14,198.4 billion, while shareholders' equity rose by 8.2% to Rp.10,217.1 billion.

While its current ratio remained healthy at approximately 2.9 times, and **net operating cycle has improved considerably to 74 days compared to 88 days in First Half 2025**. This strong liquidity position provides Tempo Scan with substantial financial flexibility to overcome challenges, support its working capital requirements, capital expenditures and strategic growth initiatives.

Closing Message

Amid continued global and domestic economic, geopolitical and policy uncertainties, Tempo Scan remains resolute in upholding its commitment to "Work Wholeheartedly for Indonesia" while advancing its strategic objectives. Tempo Scan will continue to strengthen its brand equities, expand its distribution coverage especially outside Java, increase its manufacturing capacities and productivity, enhance new products pipeline with innovation and maintain prudent financial management, in order to deliver high-quality and competitively priced products and services to its consumers.

Tempo Scan's Board of Directors would like to express its highest appreciation to its Executive Chairman & President Commissioner for pursuing the company strategies and executions, its management leadership and all employees for their dedication, commitment and relentless hard work. The Board of Directors also extends its sincere gratitude to shareholders, business partners, suppliers, healthcare professionals, customers and all stakeholders whose continued trust and support have enabled Tempo Scan to achieve the above financial results.

Jakarta, 30 July 2026
On behalf of PT Tempo Scan Pacific Tbk

Liza Prasodjo
Vice President Director

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's President Commissioner
- Tempo Scan's Board of Directors